MEDVi Pills Review: Oral Options, Costs, and What to Verify

Last reviewed: May 12, 2026 Last updated: September 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Director, with a PharmD and MBA specializing in pharmacogenomics and clinical product development. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — evidence-based guidance on GLP-1 therapies and weight-management care. Browse all Peptides & GLP-1 education

Editorial note: PlexusDx publishes this editorial review and offers one of the programs discussed. PlexusDx is not affiliated with MEDVi and has no commercial relationship with the companies named in this article; there are no affiliate links. Information is based on the sources and dates shown.

MEDVi's "pills" are two different things as of September 22, 2026: a compounded semaglutide dissolvable tablet, marketed as GLP-1 Tablets, and a branded Wegovy® pill pathway sold as a monthly membership plus separately billed medication. MEDVi's oral tablet runs about $70 a month over its injection rate for the same compound (read on its plan-selection screen); MEDVi does not publish a tablet total on its public page, so confirm the figure in MEDVi's official offer. The compounded tablet is not FDA-approved and is not the Wegovy pill. PlexusDx offers compounded Semaglutide Oral at $289/mo month-to-month, all-inclusive, with no membership fee. Your prescribing clinician decides whether an oral GLP-1 fits you at all.

What pills does MEDVi currently offer?

As of September 22, 2026, MEDVi's program page lists two oral routes. The first is a compounded semaglutide tablet, described as a daily dissolvable GLP-1 Tablet. MEDVi's plan-selection screen prices the tablet at about $70 a month over its injection rate for the same compound; MEDVi does not publish a tablet total on its public page, and none is printed here.

The second is a branded Wegovy® pill pathway. It is listed next to Wegovy® injection and Zepbound® injection as a $99 monthly membership plus the medication cost (as listed on MEDVi’s program page, September 22, 2026), with the medication billed separately and availability marked "subject to change." The medication cost is not published on the page.

What we did not find is a compounded tirzepatide tablet. Earlier versions of this review described one. The page we checked on September 22, 2026 lists compounded tirzepatide as an injection only. If a tirzepatide tablet matters to you, ask MEDVi directly rather than relying on older reviews, including older versions of this one.

MEDVi is a telehealth platform, not a clinic in itself. Prescriptions are issued by licensed providers in its network. Compounded medication is dispensed by pharmacies MEDVi names on its page: Triad Rx, RedRock Pharmacy, and Beaker Pharmacy & Compounding. For its compounded programs MEDVi states "No membership or hidden fees" and that "Medication is included in the cost of the MEDVi Program." Those are MEDVi's words, quoted here for accuracy.

Compounded tablets versus verified FDA-approved oral products

An FDA-approved oral semaglutide product exists: the Wegovy® pill from Novo Nordisk, which passed FDA review of its formulation, manufacturing, and clinical data. A compounded GLP-1 tablet is not that product. It is prepared by a state-licensed compounding pharmacy under federal compounding rules for an individual prescription. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are sold, and the agency has published its concerns about unapproved GLP-1 drugs used for weight loss.

Three distinctions matter when you read MEDVi pill reviews. First, a licensed pharmacy is not FDA approval. The license covers how the pharmacy operates, not whether the specific tablet was tested. Second, clinical-trial results for the branded Wegovy pill do not establish outcomes for a compounded tablet, because the formulation, the absorption approach, and the manufacturing controls differ. Third, all of this applies equally to PlexusDx Semaglutide Oral and Tirzepatide Oral, which are also compounded and also not FDA-approved.

On tirzepatide specifically: Eli Lilly is the only U.S. company with FDA-approved tirzepatide products. A compounded tirzepatide tablet from any telehealth program is not one of them and is not a generic or equivalent version of Zepbound® or Mounjaro®. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company; Wegovy® and Ozempic® of Novo Nordisk A/S. PlexusDx is not affiliated with or endorsed by either company.

What is known about the specific formulation?

Less than the volume of online reviews suggests. MEDVi's page describes its tablet as a daily dissolvable containing compounded semaglutide. On the page we checked, it does not publish the strengths offered, the excipients or absorption technology, which of its named pharmacies fills tablet orders, or any bioavailability data for the tablet. That is not a criticism unique to MEDVi. Compounded oral GLP-1 products across the category rarely publish that information, and PlexusDx's oral product pages describe pricing and commitment tiers, not absorption studies.

Why it matters: semaglutide is a peptide, and how much of an oral dose reaches your bloodstream depends on formulation. The branded Wegovy pill uses a specific absorption enhancer that was studied in its approval program. A compounded dissolvable tablet may take a different approach. Without published pharmacokinetic data, no one can honestly tell you that a compounded tablet delivers the same exposure as the branded pill or as a weekly injection. We do not make that claim for MEDVi's tablet, and we do not make it for PlexusDx's.

What you can verify before enrolling: which pharmacy compounds the tablet, what strength you would be started on, and how dose changes are handled and billed. Your clinician, not a review article, decides whether an oral route is suitable for you and whether a compounded tablet, an injection, or a branded product is the better fit for your history.

First-month and ongoing pill costs

MEDVi publishes a first-month price for its compounded semaglutide program: $179 for new patients, "no insurance required," as displayed on start.medvi.org on September 22, 2026. MEDVi's semaglutide injection refills are $299 per billing cycle as displayed on glp1.medvi.org the same day. Neither figure is the tablet price, so we do not present them as one. MEDVi's oral tablet runs about $70 a month over its injection rate for the same compound (read on its plan-selection screen); MEDVi does not publish a tablet total on its public page, so confirm the tablet figure in MEDVi's official offer. The branded Wegovy pill route is a monthly membership plus medication cost billed separately, and the medication cost is not published.

PlexusDx publishes this comparison and offers one of the programs discussed. Information is based on the sources and dates shown.

Checked September 22, 2026. Month-to-month rates only; compounded and branded products are shown on separate rows because they are different products. MEDVi's $179 first-month and $299 refill figures belong to its semaglutide injection program and are not shown here as tablet prices. PlexusDx prices cover the provider visit, prescription, medication, and shipping, with no membership fee.

For the detailed tablet math, including what MEDVi's page does and does not say about oral pricing, see MEDVi Oral Semaglutide Cost: Tablet Pricing and Plan Comparison. If you are weighing the injection instead, MEDVi Semaglutide Cost: Injection Prices, Refills, and Plan Terms covers the $179 first-month and $299 refill structure in depth.

MEDVi and PlexusDx oral options compared

Because MEDVi publishes no tablet total, only a premium of about $70 a month over its injection rate, an honest cost comparison has one side filled in with figures. Here is the PlexusDx side, shown month-to-month first and commitment tiers separately so you are not comparing a discounted tier against someone else's monthly rate.

Checked September 22, 2026. The 3- and 6-month figures are the advertised per-month rate on a 3- or 6-month commitment; the payment schedule and any refund terms for a multi-month plan are shown at checkout. Commitment totals are 3 × rate and 6 × rate.

Month-to-month totals for PlexusDx Semaglutide Oral are $867 for 3 cycles, $1,734 for 6 cycles, and $3,468 for 12 cycles (12 × $289). For Tirzepatide Oral they are $1,047, $2,094, and $4,188 (12 × $349). MEDVi tablet totals are not computed because MEDVi publishes no tablet total, only that the tablet runs about $70 a month over its injection rate, and MEDVi's billing-cycle length is not published, so we say "cycles" rather than "a year."

One product we deliberately keep out of the table: the PlexusDx Microdose GLP-1 Protocol at $129/mo flat. The provider selects one of four low-dose variants, delivered by injection or orally dissolving tablet. It is a different program at a different dose range, not a cheaper equivalent of a standard-dose tablet, and comparing it line-for-line against MEDVi's tablet would mislead you.

Beyond price, the programs differ in what is bundled. MEDVi's compounded programs include physician review, a personalized plan, 1:1 guidance, a metabolic report, free dietitian visits and care coaching, unlimited 24/7 support, free shipping, and HSA/FSA eligibility, per its pages. MEDVi also offers a branded pathway that PlexusDx does not. PlexusDx's specific advantages are narrower and concrete: the monthly price is flat across every dose level of a compound and changes only with commitment tier; one price covers the visit, prescription, medication, and shipping; there is no membership fee; you pay $0 until your provider approves a prescription; and month-to-month plans cancel anytime with no fees. The full side-by-side is on MEDVi vs PlexusDx: Compare GLP-1 Prices, Plans, and Support.

You can view the live PlexusDx Semaglutide Oral page and, if a dual-agonist tablet is relevant to your conversation with a clinician, the PlexusDx Tirzepatide Oral page. Neither page promises potency, absorption, or results; suitability is your provider's call.

Questions about suitability, support, and cancellation

Is an oral GLP-1 right for you?

That is a clinical decision, and neither MEDVi's intake nor PlexusDx's intake replaces it. A licensed provider reviews your history and decides whether to prescribe, which route, and at what strength. Some people prefer a daily tablet because they want to avoid injections; others do better with a weekly injection. Bring your prior GLP-1 experience, medications, and conditions to the intake, and ask the provider directly why they recommend one route over another.

What support comes with each program?

MEDVi's included services are a genuine strength: free dietitian visits and care coaching, unlimited 24/7 support, physician review, and a metabolic report, plus HSA/FSA payment. Contact channels are published (help@medvi.org, hello@medvi.org, and a phone number on its page). PlexusDx care is delivered by an independent network of U.S.-licensed clinicians through a state-licensed telehealth platform; treatment decisions are made by your prescribing clinician. Eligible adults can enroll across all 50 states, and five states require a scheduled video consultation, which your provider will advise on.

How does cancellation work?

The 72-hour rule in older reviews still holds as of September 22, 2026. MEDVi's cancellation and refund policy says you can cancel anytime, but the request must arrive at least 72 hours before your next billing date, by email to hello@medvi.org or through portal chat, and service continues to the end of the billing cycle. A full refund is available only if you cancel within the first 72 hours without receiving services, or if you are medically disqualified. On monthly billing, MEDVi states you will not be refunded for the month in which the cancellation occurs. Multi-month plans are refundable only for months with no medication shipped, consult fees are non-refundable, and prescription medication cannot be returned. The practical takeaway is to set a reminder several days before each renewal.

PlexusDx month-to-month plans cancel anytime with no fees and no long-term contract. For 3- and 6-month plans, the payment schedule and any refund terms are shown at checkout, so read that screen before you commit. A fuller walk-through of both providers' billing rules is in MEDVi Subscription: Billing, Cancellation, Pauses, and Refunds.

Where reviews fit

Most MEDVi pill reviews you will find online describe the compounded tablet, not the branded Wegovy pill pathway, and many predate the current product lineup. Read them for service themes, not for prices. Our synthesis of publicly posted MEDVi customer reviews explains what those reviews can and cannot tell you.

The next step, whichever program you lean toward, is the same: confirm the exact oral price in the official offer, read the cancellation terms, and let a licensed provider decide whether an oral GLP-1 is appropriate for you.

A note on genetics (optional)

PlexusDx offers compounded semaglutide and tirzepatide through its Weight Management Protocols. Separately, and only if it interests you, the GLP-1 & Peptide Pathways Genetic Test ($298) analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO, MC4R and TCF7L2 that relate to appetite and glucose-handling pathways. It does not predict how you will respond to any medication and does not tell you which drug, dose or provider is right for you; it is context for a conversation with your clinician. Test before you invest, and treat genetics as a guide, not a guarantee.

This article is educational. PlexusDx is not affiliated with MEDVi and has no commercial relationship with the companies discussed. PlexusDx offers compounded semaglutide and tirzepatide through its own Weight Management Protocols; this article compares approaches in the GLP-1 telehealth space. The GLP-1 & Peptide Pathways Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not predict response to any specific medication and does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol. Compounded semaglutide and tirzepatide are not FDA-approved drug products; they are prepared by state-licensed compounding pharmacies under federal compounding rules and are not the same as Wegovy®, Ozempic®, Zepbound® or Mounjaro®. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company; Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. PlexusDx is not affiliated with or endorsed by either company.

Frequently Asked Questions

What pills does MEDVi sell?

As of September 22, 2026, MEDVi's program page lists a compounded semaglutide dissolvable tablet, marketed as GLP-1 Tablets, and a branded Wegovy pill pathway sold as a monthly membership plus separately billed medication. A compounded tirzepatide tablet was not listed on the page we checked. Confirm the current lineup in MEDVi's official offer before enrolling.

Is MEDVi's compounded tablet the same as the Wegovy pill?

No. The Wegovy pill is an FDA-approved product from Novo Nordisk. MEDVi's GLP-1 Tablet is compounded by a state-licensed pharmacy for an individual prescription and has not been reviewed by the FDA for safety, effectiveness, or quality. Trial results for the branded pill do not establish outcomes for a compounded tablet. The same applies to PlexusDx oral products.

How much do MEDVi pills cost?

MEDVi's oral tablet runs about $70 a month over its injection rate for the same compound, read on its plan-selection screen September 22, 2026; MEDVi does not publish a tablet total on its public page, so confirm it in MEDVi's official offer. MEDVi's published $179 first-month price and $299 refill rate apply to its semaglutide injection program. The branded Wegovy pill route is a membership plus medication cost billed separately, with the medication cost unpublished.

How does PlexusDx Semaglutide Oral compare on price?

PlexusDx Semaglutide Oral is $289/mo month-to-month, all-inclusive, with no membership fee, and the price is flat across dose levels. Advertised commitment rates are $269/mo on a 3-month plan and $249/mo on a 6-month plan, with the payment schedule shown at checkout. Because MEDVi publishes no tablet total, only a premium of about $70 a month over its injection rate, no like-for-like total is computed.

Can I cancel MEDVi's pill program at any time?

Yes, but timing matters. MEDVi's policy requires a cancellation request at least 72 hours before your next billing date, and service continues to the end of the cycle. Full refunds apply only within the first 72 hours without services or on medical disqualification. MEDVi states no refund is issued for the month in which you cancel, and shipped medication cannot be returned.

Who decides whether a tablet or injection is right for me?

A licensed provider does, after reviewing your history during intake. Neither MEDVi's nor PlexusDx's platform makes that decision; MEDVi prescriptions come from licensed providers in its network, and PlexusDx uses an independent network of U.S.-licensed clinicians through a state-licensed telehealth platform. Ask your provider why they recommend one route, strength, or product over another.

Sources and dates checked

• MEDVi program page (glp1.medvi.org), read September 22, 2026
• MEDVi start page (start.medvi.org), first-month price, read September 22, 2026
• MEDVi cancellation and refund policy, read September 22, 2026
• FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss
• PlexusDx Semaglutide Oral product page, verified September 22, 2026
• PlexusDx Tirzepatide Oral product page, verified September 22, 2026
• PlexusDx Microdose GLP-1 Protocol product page, verified September 22, 2026

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. Sources and the dates they were checked are listed at the end of the article.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services, and offers compounded GLP-1 programs through its Weight Management Protocols. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.